Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Trumenba

    Read More

    Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants. Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.

    September 3, 2019
    Find out more
  • France, Disease Incidence and Prevalence

    $4,850.00

    As the aging population in Europe increases and the average life span lengthens, the incidence and prevalence of many major diseases/disorders are expected to increase accordingly and significantly impact the European healthcare industry.

     

    September 22, 2016
    Find out more
  • aspirin

    Aspirin

    Read More

    Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.

    July 2, 2018
    Find out more
  • 2018 Biomedtracker Datamonitor Healthcare Post-ASH Report

    $599.00

    The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.

    January 3, 2019
    Find out more
  • Oral Vidaza

    Read More

    Oral Vidaza is an orally available formulation of Vidaza (azacitidine; Celgene/Nippon Shinyaku), a small molecule cytidine nucleoside analog that exerts its anti-cancer activity through direct cytotoxicity as well as through DNA hypomethylation.

    July 6, 2017
    Find out more
  • Market Spotlight: Norovirus

    $1,318.00

    This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.

    February 17, 2022
    Find out more
  • Tezacaftor/Ivacaftor

    Read More

    Vertex’s tezacaftor (formerly known as VX-661) is a CFTR corrector compound being investigated as an adjunct to Vertex’s other marketed and developmental CFTR-targeting products. The drug’s initial development is as part of a fixed-dose combination with the CFTR potentiator ivacaftor (Vertex), which was approved with the brand name Kalydeco in January 2012.

    September 14, 2017
    Find out more
  • 2019 Post-ADA Report

    $2,995.00

    The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.

    July 22, 2019
    Find out more
  • Disease Analysis: Diabetic Nephropathy

    Read More

    Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.

    March 11, 2022
    Find out more
  • U.S. Markets for Cardiac Rhythm Management Products, February 2015

    $4,750.00

    Cardiac rhythm management (CRM) devices, which encompasses diagnostic and therapeutic systems, represents a well-established market that is still seeing innovation in some of the segments that compose it.

    February 2, 2015
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, South

    Atopic Dermatitis and Psoriasis KOL Interview – US, South

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Truvada

    Read More

    Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors (NRTIs):

    June 28, 2019
    Find out more
  • Glyxambi

    Read More

    Glyxambi is a fixed-dose combination of sodium-glucose cotransporter-2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) and dipeptidyl peptidase-IV inhibitor Tradjenta.

    November 7, 2017
    Find out more
  • Tyvaso

    Read More

    United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil

    October 29, 2018
    Find out more
  • Ketek

    Read More

    Ketek (telithromycin; Sanofi) is an oral semisynthetic antibacterial agent of the ketolide class. The drug, which is the first ketolide to gain regulatory approval for the treatment of community-acquired pneumonia, is structurally related to the macrolide class of antibiotics.

    June 19, 2015
    Find out more
  • Semaglutide (Oral)

    Read More

    Novo Nordisk’s semaglutide is an orally available GLP-1 agonist currently being investigated in Phase
    III trials for the treatment of type 2 diabetes. GLP-1 agonists are incretin mimetics, mimicking the
    endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.

    June 23, 2016
    Find out more
  • Acute Lymphocytic Leukemia KOL Interview

    $599.00

    [Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

    February 9, 2016
    Find out more
  • The Growing Impact of Real-World Evidence

    $2,995.00

    Real-world evidence (RWE) has become increasingly important in proving the value of drugs and differentiating them from their competition.

    July 14, 2017
    Find out more
  • United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Access in Emerging Markets: HTA is Making Inroads

    $2,995.00

    Generally considered the domain of developed markets, health technology assessment (HTA) is increasingly being used by developing countries as a means of reconciling growing demand for access to health technologies with limited resources. Expanding public health insurance programs, coupled with aging populations and growing patient empowerment, have led in some cases to the fast establishment […]

    November 2, 2016
    Find out more
  • Tymlos

    Read More

    Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.

    March 9, 2018
    Find out more
  • sovaldi report

    Sovaldi

    Read More

    Sovaldi (sofosbuvir; Gilead) was the first interferon-free regimen to be approved for genotype 2/3 (GT-

    2/3) patients, and has greatly benefited from the lucrative warehoused population and lack of

    competitors in this subgroup.

    November 6, 2017
    Find out more
  • U.S. Markets for Biologic and Tissue Engineered Devices – Cardiovascular and Neurological Products

    $3,750.00

    U.S. Markets for Biologic and Tissue Engineered Devices – Cardiovascular and Neurological Products, March 2015

    September 22, 2016
    Find out more
  • Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

    $599.00

    A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

    February 4, 2019
    Find out more
  • epidiolex report

    Epidiolex

    Read More

    GW Pharmaceuticals is developing Epidiolex, a first-in-class cannabinoid drug for the treatment of

    childhood seizures.

    May 23, 2017
    Find out more
  • Dyslipidemia KOL Insight Interview #2

    $599.00

    Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.

    July 28, 2014
    Find out more
  • Incruse

    Incruse

    Read More

    Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

    July 31, 2018
    Find out more
  • Market Spotlight: Gastrointestinal Stromal Tumor (GIST)

    $1,318.00

    This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.

    April 28, 2022
    Find out more
  • Napabucasin

    Read More

    Napabucasin (Dainippon Sumitomo) is designed to selectively and simultaneously inhibit multiple key pathways associated with tumor growth and development by targeting the STAT3 transcription factor.

    December 11, 2017
    Find out more
  • glaucoma

    Market Spotlight: Glaucoma

    $1,318.00

    This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    May 12, 2022
    Find out more
  • Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)

    Read More

    Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.

    February 23, 2022
    Find out more
  • Binimetinibi

    Read More

    Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway.

    May 23, 2018
    Find out more
  • Invanz

    Read More

    Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…

    June 19, 2015
    Find out more
  • Triumeq

    Read More

    Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.

    June 28, 2019
    Find out more
  • Recentin

    Read More

    Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases.

    October 30, 2015
    Find out more
  • Datamonitor Healthcare Ulcerative Colitis KOL Interviews

    $599.00

    Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.

    August 18, 2017
    Find out more
  • Abemaciclib

    Read More

    Abemaciclib is a small molecule inhibitor of cyclin-dependent kinase (CDK)4 and CDK6 in Phase III development for non-small cell lung cancer and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer by Eli Lilly

    November 14, 2016
    Find out more
  • Acute Myeloid Leukemia (AML) KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include ASTX727, guadecitabine, idasanutlin, Iomab-B, oral azacitidine, pevonedistat, and Zeltherva.

    April 1, 2020
    Find out more
  • MDS/AML KOL Interview

    $599.00

    Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

    April 9, 2015
    Find out more
  • AGS-003

    Read More

    AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).

    February 5, 2016
    Find out more
  • Nuwiq

    Read More

    Nuwiq (Octapharma) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.

    May 4, 2018
    Find out more
  • Pyridorin

    Read More

    Pyridorin’s (pyridoxamine; NephroGenex) trial program has been put on hold due to company finances

    and lack of investor/partner interest, so could well be suspended.

    April 15, 2016
    Find out more
  • Faslodex

    Read More

    Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).

    February 2, 2016
    Find out more
  • Epogen

    Read More

    Epogen is an ESA administered by intravenous or subcutaneous injection, and is indicated for the treatment of CIA.

    January 11, 2018
    Find out more
  • Global Markets for Hospital-Based Point-of-Care Diagnostic Products

    $4,750.00

    In 2015, the global point-of-care (POC) clinical diagnostic products market was valued at $14.7bn, comprising 28% of the total in-vitro diagnostics (IVD) market. The market is projected to grow at a somewhat slower rate than the overall IVD market, due mainly to a decline in the overall blood glucose self-testing segment, which comprises more than half of the POC diagnostics market.

    November 11, 2016
    Find out more
Page 1 of 29
Page 1 of 29123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top